Overview


According to FutureWise analysis the market for aromatase deficiency in 2023 is US$ 95.3 million, and is expected to reach US$ 117.1 million by 2031 at a CAGR of 2.6%.

Aromatase deficiency, also known as estrogen resistance syndrome, is a rare genetic disorder characterized by a deficiency or absence of the enzyme aromatase. Aromatase is crucial in producing estrogen, a primary female sex hormone, from precursor hormones like testosterone. In individuals with aromatase deficiency, this conversion process is impaired, leading to reduced estrogen levels in the body. This condition can affect males and females but is more commonly recognized in females. In affected females, it can lead to a range of symptoms, including delayed or absent puberty, irregular menstrual cycles, and infertility. In males with aromatase deficiency, the symptoms are often less severe and may include delayed puberty and impaired bone health.

Aromatase deficiency is diagnosed through genetic testing and biochemical assays that measure hormone levels. Treatment typically involves hormone replacement therapy to supplement the deficient estrogen. Management is tailored to the individual's needs and may include ongoing monitoring of hormone levels and bone health. Given its rarity, aromatase deficiency requires specialized medical care and expertise. Early diagnosis and intervention are crucial in managing the condition and addressing associated health concerns.

FutureWise Market Research has published a report that provides an insightful analysis of Aromatase Deficiency Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts' projects that the Aromatase Deficiency Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Sanofi
  • Pfizer, Inc.
  • GlaxoSmithKline, plc.
  • Novartis AG
  • Bayer AG
  • Eli Lilly and Company
  • MerckCo., Inc.
  • Allergan
  • Abbott
  • Merck KGaA
  • Novo Nordisk A/S
  • Genentech Inc.
  • Amgen Inc.
  • Endo International plc
  • Hisamitsu Pharmaceutical Co.,Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

Growing awareness among healthcare professionals about aromatase deficiency and advances in genetic testing and diagnostic techniques are leading to more accurate and timely diagnoses. This drives the demand for treatments and therapies for individuals with this condition.  Ongoing research efforts to understand the underlying genetic and biochemical mechanisms of aromatase deficiency contribute to targeted therapies' development. This is expected to expand treatment options for affected individuals.  Progress in hormone replacement therapies, particularly in tailoring treatments to individual patient needs, is improving the management of aromatase deficiency. This is enhancing the quality of life for individuals with the condition.

However, Aromatase deficiency is a sporadic genetic disorder, and the number of individuals affected by this condition is minor. This limited patient population can challenge pharmaceutical companies regarding market size and profitability.  Hormone replacement therapy, a primary treatment for aromatase deficiency, can be expensive. This cost may be a barrier for some individuals and limit access to optimal care. There may be a need for standardized treatment protocols due to the rarity of aromatase deficiency. This can lead to variability in care and outcomes for affected individuals and hampers the market.

By Diagnosis

  • Physical Examination
  • Gene Sequencing
  • Genetic testing
  • Others

By Treatment

  • Surgery
  • Estrogen Replacement
  • Others

By Age of Onset

  • Pediatrics
  • Adults
  • Geriatrics

By Route of Administration

  • Oral
  • Parenteral
  • Others

By End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of the region will also be provided in the final version of this market, which is based on the conclusion of primary interviews and secondary data points gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022 due to the increasing incidence of aromatase deficiency, and the subsequent rise in healthcare expenditure is anticipated to accelerate the market's growth rate in this region. Furthermore, the significant presence of key industry players is expected to boost market expansion. On contrary, the Asia-Pacific region is positioned for substantial growth in the forecast period, driven by the advancement of healthcare infrastructure. Additionally, escalating government initiatives are poised to contribute to an accelerated growth rate in this region.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Aromatase Deficiency Market By Diagnosis, By Treatment, By Age of Onset, By Route of Administration, By End-Users, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Aromatase Deficiency Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Aromatase Deficiency Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Aromatase Deficiency Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Aromatase Deficiency Market, By Diagnosis Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Physical Examination
        2. Gene Sequencing
        3. Genetic testing
        4. Others

  • 8.   Aromatase Deficiency Market, By Treatment Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Surgery
        2. Estrogen Replacement
        3. Others

  • 9.   Aromatase Deficiency Market, By Age of Onset Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Pediatrics
        2. Adults
        3. Geriatrics

  • 10.   Aromatase Deficiency Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oral
        2. Parenteral
        3. Others

  • 11.   Aromatase Deficiency Market, By End-Users Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Specialty Clinics
        3. Homecare
        4. Others

  • 12.   Aromatase Deficiency Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Online Pharmacy
        4. Others

  • 13.   North America Aromatase Deficiency Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 14.   Latin America Aromatase Deficiency Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 15.   Europe Aromatase Deficiency Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 16.   Asia Pacific Aromatase Deficiency Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 17.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 18.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 19.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. F. Hoffmann-La Roche Ltd.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Mylan N.V.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Sanofi
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Pfizer, Inc.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. GlaxoSmithKline, plc.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Novartis AG
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Bayer AG
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Eli Lilly and Company
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. MerckCo., Inc.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Allergan
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
         11. Abbott
          11.1. Company Overview
          11.2. Product Portfolio
          11.3. SWOT Analysis
          11.4. Financial Overview
          11.5. Strategic Overview
         12. Merck KGaA
          12.1. Company Overview
          12.2. Product Portfolio
          12.3. SWOT Analysis
          12.4. Financial Overview
          12.5. Strategic Overview
         13. Novo Nordisk A/S
          13.1. Company Overview
          13.2. Product Portfolio
          13.3. SWOT Analysis
          13.4. Financial Overview
          13.5. Strategic Overview
         14. Genentech Inc.
          14.1. Company Overview
          14.2. Product Portfolio
          14.3. SWOT Analysis
          14.4. Financial Overview
          14.5. Strategic Overview
         15. Amgen Inc.
          15.1. Company Overview
          15.2. Product Portfolio
          15.3. SWOT Analysis
          15.4. Financial Overview
          15.5. Strategic Overview
         16. Endo International plc
          16.1. Company Overview
          16.2. Product Portfolio
          16.3. SWOT Analysis
          16.4. Financial Overview
          16.5. Strategic Overview
         17. Hisamitsu Pharmaceutical Co., Inc.
          17.1. Company Overview
          17.2. Product Portfolio
          17.3. SWOT Analysis
          17.4. Financial Overview
          17.5. Strategic Overview

  • 20.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 21.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients